-+ 0.00%
-+ 0.00%
-+ 0.00%

IGC Pharma Announce Clinical Trial Site At Santa Cruz Behavioral In Puerto Rico For CALMA Phase 2 Clinical Trial, Investigating IGC-AD1 For Agitation In Alzheimer's Disease

Benzinga·05/22/2025 13:38:03
Listen to the news

IGC Pharma, Inc. ("IGC", or the "Company") (NYSE:IGC) today announced a clinical trial site at Santa Cruz Behavioral in Puerto Rico for its CALMA Phase 2 clinical trial, investigating IGC-AD1 for agitation in Alzheimer's disease. This strategic site directly addresses the significant impact of Alzheimer's in the region.

Approximately 12.5% of Puerto Ricans over the age of 65 have Alzheimer's, a figure notably higher than the roughly 10% prevalence observed in older non-Hispanic white populations in the U.S. This disparity is influenced by factors such as Puerto Rico's rapidly aging demographic and unique genetic predispositions. The heightened prevalence translates into a substantial economic burden, with medical care for dementia in Puerto Rico accounting for over a quarter of total societal healthcare costs, a proportion higher than in the continental U.S.